| Q2 & H1 FY26 Results Conference Call
Summary : Mankind Pharma reported strong Q2/H1 FY26 revenue growth, driven by BSV and chronic segments, but faced challenges from GST, monsoon, and talent integration, impacting margins and short-term outperformance.
Management Perspective negative : So let me be very, very candid, I mean candid with you and everybody here that we are not happy with our own performance. The kind of expectations we were having. We expected, when we started bringing transformation in Mankind, maybe in the last call or last to last call, we mentioned that, that we brought a lot of transformation in Mankind in terms of number of people. And since Mankind is a kind of a company which is basically very strong in Tier 2, Tier 3, Tier 4 kind of places, acute heavy dependent on people. And we brought a lot of changes in people. And we thought that we will be able to replace, train, make them I mean as good as the older people, those who had fantastic relationship. So we maybe over expected that. It did not happen in 9, 12 months' time. But whatever has happened has happened.
Concall Report Analysis & Insights
Business Overview
- Q2 FY26 revenue increased 21% year-on-year to INR3,697 crores, with 25% EBITDA margin.
- H1 FY26 revenue grew 23% year-on-year to INR7,268 crores, with 24.4% EBITDA margin.
- Domestic business grew 15% year-on-year, driven by chronic and BSV consolidation.
- Chronic share increased 200 bps to 37.1% in Q2, outperforming cardiac and anti-diabetics.
- Export revenue increased 83% year-on-year to INR513 crores in Q2, due to base business and BSV.
Future Growth Prospects
- Expect growth recovery in H2, with outperformance versus IPM (1.1x-1.2x).
- BSV portfolio expected to grow 18-20% for FY26, with higher growth in H2.
- Scaling digital capabilities and AI partnership for faster, smarter decision-making.
- Committed to delivering innovative, science-backed products at affordable prices.
- Strategic initiatives in BSV, including facility and R&D lab additions, are gaining momentum.
Management Insights
- Management is not satisfied with current performance, acknowledging over-expectation from recent transformations.
- Significant organizational changes were implemented across domestic, BSV, and OTC divisions for long-term growth.
- Expect performance to improve and outperform IPM in Q3 and Q4.
- Committed to maintaining competitive pricing, ensuring affordability and value addition.
- R&D expenses are within guidance of 2.5% to 3% of sales, reflecting commitment to innovation.
Signs of Skepticism
- Domestic secondary sales growth (6.3%) was lower than IPM growth (7.2%).
- Management admitted over-expecting the immediate performance of new talent post restructuring.
- OTC business revenue declined 3% year-on-year due to GST and monsoon impact.
- The gap in chronic outperformance versus IPM has reduced in recent quarters.
- EBITDA margin declined by 280 basis points year-on-year in Q2.
Risk Factors
- Supply chain disruption due to new GST rates impacted domestic and OTC sales.
- Uneven monsoon caused some impact on OTC business.
- Higher employee costs due to increment cycle, headcount increase, and sales force restructuring.
- Overestimation of new talent's immediate performance post organizational changes.
- Profit after tax decreased 21.3% year-on-year due to higher finance and depreciation costs.
Good To Know
- Launched Mankind University, an AI-powered virtual learning platform for organizational development.
- Net debt reduced to INR4,791 crores, with net debt to adjusted EBITDA ratio improving to 1.4x.
- Commercial papers worth INR5,000 crores were fully retired by October 2025.
- R&D expenses increased to 2.9% of sales in Q2 FY26, in line with guidance.
- Depreciation and amortization increased due to BSV asset consolidation.
Key Drivers
- BSV integration drives sequential growth.
- Chronic portfolio outperforms market trends.
- Digital transformation enhances operations.
- Strong export revenue growth continues.
Key Analyst Discussions
Competitive Environment
- Discussion on maintaining a price gap with competitors despite recent price hikes.
- Management noted that Mankind's price increase (3.9%) was slightly lower than IPM (4.2%).
- Questions about the reduced outperformance gap versus IPM in chronic segment.
- Management emphasized historical outperformance as key to becoming the fourth-largest company.
Market Trends & Consumer Behavior
- GST 2.0 rollout caused brief market disruption, particularly in Tier 2-6 cities and acute business.
- Uneven monsoon impacted OTC sales due to reduced reach and inventory push.
- Secondary sales of key OTC brands (Manforce, Gas-O-Fast) showed healthy growth.
- Modern trade and e-commerce share expanded to 12% in H1 FY26 from 8% last year.
Financial Highlights
- Analysts questioned organic export growth, which was confirmed as mid-single digits (5%).
- Queries on BSV profitability, expected to reach 26-28% in H2 FY26.
- Employee cost increase attributed to increment cycle, headcount, and sales force restructuring.
- R&D guidance of 2.5-3% of sales for the full year was maintained.
- EBITDA margin guidance of 25-26% for FY26 is maintained, likely at the lower end.
Product Composition
- BSV domestic specialty business showed double-digit sequential growth.
- Inhaler brands (Symbicort, Combihale) showed strong growth, with increased doctor coverage.
- R&D investments in BSV include recombinant niche biologicals and immunoglobulins.
- Panacea portfolio expected to grow 15-20% this year, slightly lower than previous 25% plus.
Strategic Considerations
- Inquiries about cost synergies from BSV acquisition, primarily revenue-driven.
- Management discussed challenges in integrating new talent and transforming the organization.
- Focus on consolidating market share of recent good launches.
- Long-term strategy aims for continued outperformance beyond H2 FY26's 1.1x-1.2x IPM.